<span item_type="fundamental" item_id="f1e64ffa3ad9a4b36b65cb1bd2e50ceb" counter_id="ST/US/PAVM" env="prod"></span><span item_type="announcement" item_id="582312295501596033" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 5 K, missing the estimate of USD 12.5 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.29.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -4.846 M.</p><p></p><h3>Financial Results</h3><h4>Operating Expenses</h4><ul><li>For the three months ended September 30, 2025, operating expenses were approximately $4.8 million, including stock-based compensation expenses of $0.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>GAAP net loss attributable to common stockholders was approximately $6.3 million, or - $0.29 per common share on a diluted basis.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul><h4>Non-GAAP Adjusted Loss</h4><ul><li>The non-GAAP adjusted loss was approximately $0.4 million or - $0.02 per common share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>PAVmed had cash and cash equivalents of $3.1 million as of September 30, 2025, compared to $1.2 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><h4>EsoGuard Revenue</h4><ul><li>Lucid Diagnostics recognized $1.2 million in revenue from the EsoGuard Esophageal DNA Test for the third quarter of 2025 and processed 2,841 EsoGuard tests.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>PAVmed expects to benefit from the success of its subsidiaries as they advance toward major milestones, including Veris’s FDA submission for its implantable physiological monitor and Lucid’s approach to transformative Medicare coverage for EsoGuard.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/ex99-1.htm"></span></li></ul>

PAVmed | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 5 K